Skip to main content
. 2021 Mar 31;12(11):3145–3153. doi: 10.7150/jca.56097

Figure 1.

Figure 1

Expression of CDC37L1 in GC samples and relation with the clinicopathological factors. (a) Characterization of CDC37L1 protein expression in weak, moderate and strong GC specimens by immunohistochemistry staining (left). The correlation between staining of CDC37L1 and histological grade (right). (b) Differential transcriptional expression of CDC37L1 in normal samples and GC samples within individual cancer stages. (c) According to Kaplan-Meier survival curves, OS rate in patients with low expression of CDC37L1 (black line; n=395; P<0.01, log-rank test) was significantly lower than that in patients with high expression of CDC37L1 (red line; n=481).